Scientists set to develop next-generation anti-rabies biologics
-
Last Update: 2020-07-04
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sanofi Pasteur has announcedwill work with Crucell to develop a new generation of rabies-resistant monoclonal antibodies,for the use ofin conjunction with rabies vaccine,post-exposure prevention of rabies, a deadlydiseaseReporters recently learned from Sanofi Pasteur's agency in China
rabies once the incidence of,death rate is very highTherefore, the dog and other mammals seriously bitten, must use active and passive immunity two means to preventActive immunity refers to rabies vaccination, passive immunity refers to the injection of rabies immunoglobulinAs a new biological product, rabies monoclonal antibodies have the potential to replace rabies immunoglobulins currently in useCrucell has successfully developed rabies bioproducts made from two monoclonal antibodiesPreclinical studies and phase I clinical trials have shown that this product is more effective than immunoglobulins currently in use and can quickly produce neutralized effects on rabies viruses
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
